FDA Orange Book · active-ingredient family
Tafluprost
Tafluprost is approved as 1 brand and 3 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:ZIOPTAN · NDA 202514
1
Brand (NDA)
3
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution/drops
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ZIOPTANRLD | THEA PHARMA | NDA 202514 | AT | Feb 10, 2012 |
Generic (ANDA) products (3)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| TAFLUPROST | INGENUS PHARMS LLC | ANDA 218002 | AT | Apr 05, 2024 | |
| TAFLUPROST | SANDOZ | ANDA 209040 | AT | Jan 28, 2022 | |
| TAFLUPROST | MICRO LABS | ANDA 209051 | AT | Aug 19, 2019 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10864159 | May 28, 2029 | in 3 yr | ProductU-778 |
| 9999593 | May 28, 2029 | in 3 yr | Product |
Tafluprost — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
